Northern Institute for Cancer Research

Staff Profile

Dr Al Gabriel

Research Associate



2011 - PhD Genetics, University of Kent

2006 - BSc. (Hons) Genetics, University of London

Previous Positions

2010-2011 - Research Assistant: University of Oxford



Honours and Awards

2018 - £6,473  CCLG Tissue Bank Pilot Grant programme (Principal investigator)

2017 - £500 travel grant from Action Medical Research to attend SIOPEN 2017

2016 - £450 travel grant to attend NCRI 2016, Liverpool

2016 - £450 travel grant from Newcastle University to attend SIOP 2016, Dublin

2015 - €500 travel grant from the European Hematology Association

Roles and Responsibilities

Training and supervision of undergraduate and postgraduate students

Member of Athena Swan Self- Assessment Team (SAT)


Research Interests


Despite advances in neuroblastoma therapy relapse still occurs in 50% of high risk cases and in most high risk cases cure is no longer possible. Recent studies report an increased frequency of recurrent, genetic abnormalities at relapse including segmental chromosomal abnormalities (SCA)  and gene mutations for which targeted treatments exist e.g. anaplastic lymphoma kinase gene (ALK)  and RAS-MAPK pathway mutations. Identification of new genetic abnormalities at relapse is important to predict response to existing targeted agents e.g. ALK inhibitors, but moreover to identify potential new treatment targets. By studying paired tumours at diagnosis and relapse we are attempting to determine whether these genetic abnormalities are present in a sub-clone at diagnosis, at what frequency, and if so whether we should be considering upfront treatment with targeted therapies


Little Princess Trust

Action Medical Research

Great Ormond Street Hospital Children's Charity